ERBB2 and cancer: Vaccines have a number of advantages compared to standard cancer treatments like chemotherapy and anti-HER2-immunotherapy via monoclonal antibodies: better tolerance, lower toxicity, and a long-lasting immune response with tumor specificity [411].